A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Tetanus Clinical Trial

Official title:

A Randomized, Blinded, Controlled Phase I Clinical Trial for Preliminary Evaluation of the Safety and Immunogenicity of Adsorbed Cell-free DPT Vaccine (for People Aged 6 Years and Above)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06056050
• Other study ID #: CTP-Tdcp-001
• Status: Recruiting
• Phase: Phase 1
• Start date: December 6, 2023
• Est. completion date: February 28, 2025

Study information

• Verified date: August 2023
• Source: CanSino Biologics Inc.
• Contact: Jingxuan Wan
• Phone: 022-58213600-6051
• Email: jingxuan.wan[@]cansinotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, diphtheria is an acute upper respiratory infectious disease caused by Gram-positive Corynebacterium diphtheriae, and tetanus is a highly fatal disease caused by Clostridium tetani infection. Currently, there is no clinical trial registration of Diphtheria, tetanus, and pertussis (DPT) vaccine applicable to ≥6 years of age in China, therefore, the five-component acellular DPT combination vaccine developed by our research has a promising future.

Description:

The vaccines used in China's immunization program for the prevention of pertussis, tetanus and diphtheria include the adsorbed cell-free diphtheria-tetanus-acellular pertussis vaccine (DTaP) and the diphtheria-tetanus-acellular tetanus vaccine (DT) and tetanus vaccine. Among them, DTaP vaccination is for children from 3 months of age to 6 years of age, with one dose each at 3, 4, 5, and 18 months of age; DT vaccination is for children under 12 years of age, with one dose at 6 weeks of age after completing four doses of DTaP vaccination. However, infant and young child vaccination is no longer sufficient to prevent the threat of this disease, mainly due to the rapid decay of immune protection in adolescents and adults, and infections in this population, which are the main source of infection leading to infection in infants and young children, have been a number of new preventive strategies are being evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: February 28, 2025
• Est. primary completion date: February 28, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

• = 6 years of age.

• Willingness to provide proof of identity.

• The informed consent of the volunteer and/or the guardian and/or the delegate must be obtained and the informed consent form must be signed.

• Volunteers are able and willing to comply with the requirements of the clinical trial protocol and are able to complete the full study follow up.

• Volunteers aged 6-11 years who have completed 4 doses of DPT-containing vaccine, but have not received the 5th dose, and have =3 years between the 4th dose.

• Volunteers aged =12 years must not have received any of the components of the DPT-containing vaccine within 5 years.

Exclusion Criteria:

• Persons with fever prior to vaccination, with axillary temperature > 37.0°C.

• A female with a positive urine pregnancy test or a breastfeeding volunteer, where the volunteer or her partner has a plan to become pregnant within 180 days.

• Adults with severe cardiovascular disease, hypertension (systolic blood pressure =160mmHg, diastolic blood pressure =100mmHg) that cannot be controlled by medication, or other severe chronic diseases.

• Abnormal and clinically significant results of preimmunization blood tests, blood biochemistry and urine tests.

• Persons who have suffered from one of the diseases of diphtheria or tetanus, or who have suffered from whooping cough in the last three years.

• Volunteers =12 years of age who have received pneumococcal polysaccharide/conjugate-containing vaccine within 4 years.

• Individuals who have had household contact with individuals diagnosed with pertussis, diphtheria, tetanus in the past 30 days.

• Individuals who are allergic to the components of the study vaccine or who have developed an allergy during previous administration of the same vaccine; individuals with a previous history of severe allergies, such as urticaria, anaphylaxis, respiratory distress, angioneurotic edema, or asthma.

• History of convulsions, epilepsy, encephalopathy and serious neurological disorders (e.g., transverse myelitis, Guillain-Barre syndrome, demyelinating diseases, etc.), etc.

• Individuals with primary and secondary immune impairment (history of thyroid, pancreas, liver, spleen, kidney disease or removal, or need for treatment due to thyroid disease within the past 12 months), who have received immunosuppressive therapy within 3 months.

• Physician-diagnosed coagulation abnormalities (e.g., coagulation factor deficiencies, coagulopathies, platelet abnormalities) or significant bruising or coagulation disorders.

• Persons with acute febrile illnesses and current patients with infectious diseases who have had a history of moderately high fever (axillary temperature =38.0°C) or cardiopulmonary disease (frequent asthma attacks) within the past 3 days.

• Has received another investigational drug or vaccine within 1 month prior to receiving the experimental drug, or is planning to participate or is participating in a clinical study of any other drug.

• Received live attenuated vaccine within 14 days prior to receiving the test drug and subunit vaccine or inactivated vaccine within 7 days prior to receiving the test drug.

• Any other factors that, in the judgment of the investigator, make the volunteer unsuitable for participation in a clinical trial.

Related Conditions & MeSH terms

• Diphtheria
• Pertussis
• Tetanus

Intervention

Biological:
• Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Aged 6 Years and Older) (Tdcp)
1 dose of Tdcp vaccine (0.5ml) on Day 0
• 23-Valent Pneumococcal Polysaccharide Vaccine(PPV23)
1 dose of PPV23 vaccine (0.5ml) on Day 0
• Diphtheria and Tetanus Combined Vaccine, Adsorbed (DT)
1 dose of DT vaccine (0.5ml) on Day 0

Locations

Country	Name	City	State
China	Shaanxi Center for Disease Control and Prevention	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
CanSino Biologics Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse reactions 0-30 days after vaccination		0-30 days after vaccination
Secondary	Incidence of adverse reactions within 30 minutes of vaccination		Within 30 minutes of vaccination
Secondary	Incidence of adverse reactions/adverse events 0-7 days after vaccination		0-7 days after vaccination
Secondary	Incidence of adverse events 0-30 days after vaccination		0-30 days after vaccination
Secondary	Incidence of severe adverse events (SAE) 360 days after vaccination in the 6-11 years old group		360 days after vaccination
Secondary	Incidence of SAE 180 days after vaccination in the 12-17 year old group and the =18 years old group		180 days after vaccination
Secondary	Hemoglobin content (HGB) on day 4 after vaccination		Day 4 after vaccination
Secondary	White blood cell count on day 4 after vaccination		Day 4 after vaccination
Secondary	Alanine aminotransferase (ALT) in blood on day 4 after vaccination		Day 4 after vaccination
Secondary	Aspartate aminotransferase (AST) in blood on day 4 after vaccination		Day 4 after vaccination
Secondary	Total bilirubin (TBIL) in blood on day 4 after vaccination		Day 4 after vaccination
Secondary	Protein in urine on day 4 after vaccination		Day 4 after vaccination
Secondary	Erythrocytes in urine on day 4 after vaccination		Day 4 after vaccination
Secondary	Antibody Positive Turnover of Serum Anti-Diphtheria Toxoid(DT), Tetanus Toxoid(TT), Pertussis Toxoid(PT), Filamentous hemagglutmin(FHA), Pertactin(PRN), FIM bridal agglutinogens(FIM) 2&3 at 30 days after vaccination		30 days after vaccination
Secondary	Antibody Positivity of Serum Anti-DT, TT, PT, FHA, PRN, FIM 2&3 at 30 days after vaccination		30 days after vaccination
Secondary	Geometric Mean Concentration (GMC) of Serum Anti-DT, TT, PT, FHA, PRN, FIM 2&3 at 30 days after vaccination		30 days after vaccination
Secondary	Proportion of serum anti-PRN, FIM 2&3 antibodies =5, 10, 20 IU/ml 30 days after vaccination		30 days after vaccination